Patient characteristics at first AML diagnosis
| Characteristic . | Development cohort (N = 943) . |
|---|---|
| Age at relapse, median (range), y | 58.0 (18.0-81.0) |
| Sex, n (%) | |
| Male | 523 (55.5) |
| Female | 420 (44.5) |
| WBC (at diagnosis), median (range), ×109/L | 8.45 (0-510) |
| ELN risk at diagnosis, n (%) | |
| Favorable | 204 (21.6) |
| Intermediate | 289 (30.6) |
| Adverse | 450 (47.7) |
| Best response within 2 induction cycles, n (%) | |
| CR | 889 (94.3) |
| CRi | 54 (5.7) |
| HCT in first CRi, n (%) | |
| No | 506 (53.7) |
| Allogeneic | 310 (32.9) |
| Autologous | 127 (13.5) |
| Relapse-free interval, median (range), mo | 8 (0-124) |
| Follow-up of patients alive after first relapse, median (range), mo | 49 (0-128) |
| Characteristic . | Development cohort (N = 943) . |
|---|---|
| Age at relapse, median (range), y | 58.0 (18.0-81.0) |
| Sex, n (%) | |
| Male | 523 (55.5) |
| Female | 420 (44.5) |
| WBC (at diagnosis), median (range), ×109/L | 8.45 (0-510) |
| ELN risk at diagnosis, n (%) | |
| Favorable | 204 (21.6) |
| Intermediate | 289 (30.6) |
| Adverse | 450 (47.7) |
| Best response within 2 induction cycles, n (%) | |
| CR | 889 (94.3) |
| CRi | 54 (5.7) |
| HCT in first CRi, n (%) | |
| No | 506 (53.7) |
| Allogeneic | 310 (32.9) |
| Autologous | 127 (13.5) |
| Relapse-free interval, median (range), mo | 8 (0-124) |
| Follow-up of patients alive after first relapse, median (range), mo | 49 (0-128) |
CRi, CR with incomplete count recovery.